PMC:7160875 / 2699-3856 JSONTXT

{"project":"TEST0","denotations":[{"id":"32313499-160-165-4302","span":{"begin":160,"end":161},"obj":"[\"15281961\"]"},{"id":"32313499-237-242-4303","span":{"begin":558,"end":559},"obj":"[\"25340436\"]"},{"id":"32313499-75-80-4304","span":{"begin":1030,"end":1031},"obj":"[\"18570291\"]"},{"id":"32313499-77-82-4305","span":{"begin":1032,"end":1033},"obj":"[\"30610090\"]"},{"id":"32313499-109-114-4306","span":{"begin":1064,"end":1065},"obj":"[\"25921215\"]"}],"text":"Magnetoencephalography (MEG) for the localization of the epileptogenic zone entered clinical practice in the late 1990s and was routinely used by the mid-2000s.1 Since that time, the adoption of this technology by the epilepsy community has been steady but slow. Although there are currently over 25 clinical MEG centers in the United States performing epilepsy studies, many academic centers and large epilepsy practices do not have on-site MEG access in the same manner as say, the now ubiquitous 3T MRI scanner which became commercially available in 1998.2 The fact that the MEG scanner needs to be housed in a special magnetically shielded room and the entire system costs over US $2M (personal communication) may factor into the slow adoption rate. However, the statement that MEG provides added value to the presurgical workup of select patients with epilepsy should not be a controversial one and not likely to be the reason for the slow adoption. From a scientific perspective, there have been numerous prospective studies3,4 and retrospective large series5 which have established the efficacy and safety of MEG in localizing the epileptogenic zone."}

{"project":"0_colil","denotations":[{"id":"32313499-15281961-4302","span":{"begin":160,"end":161},"obj":"15281961"},{"id":"32313499-25340436-4303","span":{"begin":558,"end":559},"obj":"25340436"},{"id":"32313499-18570291-4304","span":{"begin":1030,"end":1031},"obj":"18570291"},{"id":"32313499-30610090-4305","span":{"begin":1032,"end":1033},"obj":"30610090"},{"id":"32313499-25921215-4306","span":{"begin":1064,"end":1065},"obj":"25921215"}],"text":"Magnetoencephalography (MEG) for the localization of the epileptogenic zone entered clinical practice in the late 1990s and was routinely used by the mid-2000s.1 Since that time, the adoption of this technology by the epilepsy community has been steady but slow. Although there are currently over 25 clinical MEG centers in the United States performing epilepsy studies, many academic centers and large epilepsy practices do not have on-site MEG access in the same manner as say, the now ubiquitous 3T MRI scanner which became commercially available in 1998.2 The fact that the MEG scanner needs to be housed in a special magnetically shielded room and the entire system costs over US $2M (personal communication) may factor into the slow adoption rate. However, the statement that MEG provides added value to the presurgical workup of select patients with epilepsy should not be a controversial one and not likely to be the reason for the slow adoption. From a scientific perspective, there have been numerous prospective studies3,4 and retrospective large series5 which have established the efficacy and safety of MEG in localizing the epileptogenic zone."}

{"project":"2_test","denotations":[{"id":"32313499-15281961-28641131","span":{"begin":160,"end":161},"obj":"15281961"},{"id":"32313499-25340436-28641132","span":{"begin":558,"end":559},"obj":"25340436"},{"id":"32313499-18570291-28641133","span":{"begin":1030,"end":1031},"obj":"18570291"},{"id":"32313499-30610090-28641134","span":{"begin":1032,"end":1033},"obj":"30610090"},{"id":"32313499-25921215-28641135","span":{"begin":1064,"end":1065},"obj":"25921215"}],"text":"Magnetoencephalography (MEG) for the localization of the epileptogenic zone entered clinical practice in the late 1990s and was routinely used by the mid-2000s.1 Since that time, the adoption of this technology by the epilepsy community has been steady but slow. Although there are currently over 25 clinical MEG centers in the United States performing epilepsy studies, many academic centers and large epilepsy practices do not have on-site MEG access in the same manner as say, the now ubiquitous 3T MRI scanner which became commercially available in 1998.2 The fact that the MEG scanner needs to be housed in a special magnetically shielded room and the entire system costs over US $2M (personal communication) may factor into the slow adoption rate. However, the statement that MEG provides added value to the presurgical workup of select patients with epilepsy should not be a controversial one and not likely to be the reason for the slow adoption. From a scientific perspective, there have been numerous prospective studies3,4 and retrospective large series5 which have established the efficacy and safety of MEG in localizing the epileptogenic zone."}

{"project":"MyTest","denotations":[{"id":"32313499-15281961-28641131","span":{"begin":160,"end":162},"obj":"15281961"},{"id":"32313499-25340436-28641132","span":{"begin":558,"end":560},"obj":"25340436"},{"id":"32313499-18570291-28641133","span":{"begin":1030,"end":1031},"obj":"18570291"},{"id":"32313499-30610090-28641134","span":{"begin":1032,"end":1034},"obj":"30610090"},{"id":"32313499-25921215-28641135","span":{"begin":1064,"end":1066},"obj":"25921215"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Magnetoencephalography (MEG) for the localization of the epileptogenic zone entered clinical practice in the late 1990s and was routinely used by the mid-2000s.1 Since that time, the adoption of this technology by the epilepsy community has been steady but slow. Although there are currently over 25 clinical MEG centers in the United States performing epilepsy studies, many academic centers and large epilepsy practices do not have on-site MEG access in the same manner as say, the now ubiquitous 3T MRI scanner which became commercially available in 1998.2 The fact that the MEG scanner needs to be housed in a special magnetically shielded room and the entire system costs over US $2M (personal communication) may factor into the slow adoption rate. However, the statement that MEG provides added value to the presurgical workup of select patients with epilepsy should not be a controversial one and not likely to be the reason for the slow adoption. From a scientific perspective, there have been numerous prospective studies3,4 and retrospective large series5 which have established the efficacy and safety of MEG in localizing the epileptogenic zone."}